Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2022-08-26 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BOTHE_PR_2022-09-05_EGM1_FR_vfinal.pdf
AGM Information Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release - Regulated Information) and its primary subject is the announcement that Bone Therapeutics will hold an Extraordinary General Meeting (Assemblée Générale Extraordinaire) on October 5, 2022, having rescheduled it from September 26, 2022. It explicitly states that the official notices (convocations) containing the agenda and draft resolutions are being published today in official gazettes ("Le Moniteur Belge et La Libre Belgique"). It also mentions that preparatory documents are made available on the company website. This structure—a short press release announcing the scheduling and availability of materials for a shareholder meeting—strongly indicates a communication related to soliciting votes or providing information ahead of a meeting, which aligns best with the Proxy Solicitation & Information Statement (PSI) definition. However, since the core action is the announcement of the meeting details and the availability of related documents, and given the context of shareholder meetings, AGM-R (AGM Information) is also a strong candidate, but AGM-R usually implies the presentation materials themselves. Since this is a regulatory announcement *about* the meeting and the availability of documents, and it is not the final voting results (DVA) or the formal proxy statement (PSI) itself, it functions as a general announcement related to the AGM. Given the specific mention of reconvening the 'assemblée générale extraordinaire' and the availability of preparatory documents, AGM-R is the most fitting category for materials directly related to the AGM process, even if it's the announcement of the meeting itself, as opposed to a general regulatory filing (RNS). If the document were purely about the *process* of soliciting votes (like a definitive proxy statement), PSI would be better, but this is a notice about the meeting date and document availability. I will classify it as AGM-R as it directly concerns the Annual General Meeting logistics.
2022-08-26 French
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_EN_Final.pdf
M&A Activity Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE – INSIDE INFORMATION" dated August 10, 2022. It announces a significant corporate action: the acquisition of a majority stake in Medsenic by Bone Therapeutics, leading to a business combination and a proposed name change to 'BioSenic'. This type of announcement, detailing a major transaction, management changes, and future financing plans, is typically classified as a major corporate event disclosure. Since it is a press release announcing a strategic transaction (M&A activity) and not the final regulatory filing (like a 10-K or IR), the most appropriate category is related to corporate actions or major announcements. While 'TAR' (M&A Activity) is relevant, the document is structured as a general regulatory disclosure/press release about a significant event, often falling under 'RNS' (Regulatory Filings) if a more specific category like 'TAR' isn't strictly defined for press releases about M&A. However, given the core subject is the acquisition/combination, 'TAR' (M&A Activity) is the most specific fit for the content, even if it's presented as a press release. Since the definitions do not explicitly list a 'Press Release' category, and this is a major transaction announcement, I will prioritize the subject matter over the format, but acknowledge that 'RNS' is a strong fallback. Given the detailed terms of the combination, 'TAR' is the best fit for the substance.
2022-08-26 English
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_FR_Final.pdf
M&A Activity Classification · 99% confidence The document text describes a definitive agreement for Bone Therapeutics to acquire a majority stake in Medsenic, leading to a combination of operations and the creation of a new entity, BioSenic. It details the terms of the exchange, the rationale for the merger, planned changes to the Board of Directors, and future financing plans. This announcement concerns a significant corporate transaction (Merger/Acquisition) and subsequent capital structure/governance changes. While it mentions an upcoming Extraordinary General Meeting ('AGE') to approve the merger, the primary focus and content are the details of the M&A transaction itself. Therefore, the most appropriate classification is M&A Activity (TAR).
2022-08-26 French
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_EN_Final.pdf
M&A Activity Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE – INSIDE INFORMATION" dated August 10, 2022. It announces a significant corporate action: the acquisition of a majority stake in Medsenic by Bone Therapeutics, leading to a business combination and a proposed name change to 'BioSenic'. This type of announcement, detailing a major transaction, management changes, and future financing plans, is typically classified as a major corporate event disclosure. Since it is a press release announcing a strategic transaction (M&A activity) and not the final regulatory filing (like a 10-K or IR), the most appropriate category is related to corporate actions or major announcements. While 'TAR' (M&A Activity) is relevant, the document is structured as a general regulatory disclosure/press release about a significant event, often falling under 'RNS' (Regulatory Filings) if a more specific category like 'TAR' isn't strictly defined for press releases about M&A. However, given the core subject is the acquisition/combination, 'TAR' (M&A Activity) is the most specific fit for the content, even if it's presented as a press release. Since the definitions do not explicitly list a 'Press Release' category, and this is a major transaction announcement, I will prioritize the subject matter over the format, but acknowledge that 'RNS' is a strong fallback. Given the detailed terms of the combination, 'TAR' is the best fit for the substance.
2022-08-10 English
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_FR_Final.pdf
M&A Activity Classification · 99% confidence The document announces a significant corporate action: the acquisition of a majority stake in Medsenic by Bone Therapeutics, leading to the creation of a new entity, BioSenic. This involves an exchange of shares, changes in capital structure, and proposed changes to the Board of Directors. This type of transaction—a merger or acquisition proposal—directly corresponds to the 'M&A Activity' category. The document details the terms of the exchange, the rationale, and the future structure, making 'TAR' (M&A Activity) the most appropriate classification, rather than a general regulatory filing (RNS) or a financing update (CAP), as the core event is the combination of two companies.
2022-08-10 French
BOTHE_PR_2022-07-29_Denominator_EN_vFinal.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly labeled as a "PRESS RELEASE - REGULATED INFORMATION" dated July 29, 2022. The core content details an "increase in the total number of voting rights and shares" due to the conversion of convertible bonds, providing specific tables showing the change in share capital and the total number of shares with voting rights. This directly relates to changes in the company's capital structure and share count, which is a mandatory disclosure under regulations (Article 15 of the Belgian Law mentioned). This type of filing, announcing changes in the number of shares outstanding, aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a full Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it concerns a specific, quantifiable change in capital structure.
2022-07-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.